Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease

被引:41
作者
Matsuda, Shogo [1 ]
Kotani, Takuya [1 ]
Ishida, Takaaki [1 ]
Fukui, Keisuke [2 ]
Fujiki, Youhei [1 ]
Suzuka, Takayasu [1 ]
Nagai, Koji [1 ]
Hata, Kenichiro [1 ]
Shoda, Takeshi [3 ]
Isoda, Kentaro [3 ]
Ito, Yuri [2 ]
Makino, Shigeki [1 ]
Takeuchi, Tohru [1 ]
Arawaka, Shigeki [1 ]
机构
[1] Osaka Med Coll, Dept Internal Med 4, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan
[2] Osaka Med Coll, Res & Dev Ctr, Dept Med Stat, Takatsuki, Osaka, Japan
[3] Yodogawa Christians Hosp, Dept Rheumatol, Osaka, Japan
关键词
polymyositis; dermatomyositis; interstitial lung disease; cytokines; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; MYOSITIS; PROGNOSIS; ANTIBODY; FERRITIN; PROGRESS; MDA5;
D O I
10.1093/rheumatology/kez301
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To elucidate the serum cytokine profile and address the pathomechanism of interstitial lung disease (ILD) complicated with PM/DM. Methods Forty patients with PM/DM-ILD were enrolled, and principal components analysis and cluster analysis were performed to classify patients into subgroups. Additionally, we compared cytokine profiles between the survivors and dead patients and between anti-melanoma differentiation-associated gene 5 antibody- and anti-aminoacyl tRNA synthetase antibody-positive ILD patients. We also examined the association of various cytokines with disease activity indicators and prognosis of ILD. Results The principal components analysis data allowed classification of the cytokine profile into three groups: group 1, neutrophilic and M1-macrophage-driven cytokines; group 2, type 1 Th cell-driven and M2-macrophage-induced cytokines; and group 3, M2-macrophage-driven cytokines. Cluster analysis showed the presence of PM/DM-ILD patient groups with high or low levels of total cytokines. Ninety percent of patients who died of ILD were included in clusters with high cytokine levels. Serum cytokine levels of all groups were significantly higher in the anti-melanoma differentiation-associated gene 5 antibody-positive patients than in the anti-aminoacyl tRNA synthetase antibody-positive patients. Groups 1 and 2 significantly correlated with known factors for poor prognosis, such as serum ferritin levels and alveolar-arterial oxygen difference. Serum cytokine levels of patients in group 1 were significantly higher initially and at 2 and 4 weeks in those who died. Conclusion These findings suggested that the activation of monocytes, macrophages and type 1 Th cells, and neutrophils play roles in the pathomechanism of PM/DM-ILD, and group 1 cytokines could be useful biomarkers for predicting prognosis of PM/DM-ILD.
引用
收藏
页码:310 / 318
页数:9
相关论文
共 50 条
[41]   miR-1 is a novel biomarker for polymyositis/dermatomyositis-associated interstitial lung disease [J].
Sugiyama, Yumiko ;
Yoshimi, Ryusuke ;
Takeno, Mitsuhiro ;
Kunishita, Yosuke ;
Kishimoto, Daiga ;
Kamiyama, Reikou ;
Kirino, Yohei ;
Ohno, Shigeru ;
Nakajima, Hideaki .
MODERN RHEUMATOLOGY, 2020, 30 (05) :878-883
[42]   Plasma levels of adhesion molecules are elevated in dermatomyositis-interstitial lung disease and associated with low paraoxonase-1 activity [J].
Bae, Sangmee Sharon ;
Shahbazian, Ani ;
Wang, Jennifer ;
Markovic, Daniela ;
De Leon, Tiffany ;
Lee, Yuna ;
Reddy, Srinivasa T. ;
Charles-Schoeman, Christina .
ARTHRITIS RESEARCH & THERAPY, 2025, 27 (01)
[43]   Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study [J].
Maho Nakazawa ;
Yuko Kaneko ;
Tsutomu Takeuchi .
Clinical Rheumatology, 2018, 37 :765-771
[44]   Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis [J].
Ochi, S ;
Nanki, T ;
Takada, K ;
Suzuki, R ;
Komano, Y ;
Kubota, T ;
Miyasaka, N .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (05) :707-710
[45]   Polymyositis-dermatomyositis-associated interstitial lung disease [J].
Douglas, WW ;
Tazelaar, HD ;
Hartman, TE ;
Hartman, RP ;
Decker, PA ;
Schroeder, DR ;
Ryu, JH .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (07) :1182-1185
[46]   Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis [J].
Zhang, Li ;
Wu, Guoqin ;
Gao, Di ;
Liu, Guijian ;
Pan, Lin ;
Ni, Liyan ;
Li, Zheng ;
Wang, Qiang .
PLOS ONE, 2016, 11 (05)
[47]   Serum Interleukin-18 Level is Associated With Disease Activity and Interstitial Lung Disease in Patients With Dermatomyositis [J].
Yang, Yuan ;
Yin, Geng ;
Hao, Jingcheng ;
Xie, Qibing ;
Liu, Yi .
ARCHIVES OF RHEUMATOLOGY, 2017, 32 (03) :181-188
[48]   Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study [J].
Ji Su-yun ;
Zeng Fan-qin ;
Guo Qing ;
Tan Guo-zhen ;
Tang Hong-feng ;
Luo Yi-jin ;
Tang Zeng-qi ;
Han Yan-fang .
CHINESE MEDICAL JOURNAL, 2010, 123 (05) :517-522
[49]   A clinical analysis of prognostic factors for dermatomyositis-associated interstitial lung disease [J].
Zhang, Ti ;
Zhang, Ju ;
Liu, Xin ;
Zhang, Lanling ;
Zhao, Dongbao ;
Wu, Xin ;
Xu, Huji .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (06) :5903-5911
[50]   Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants [J].
Takada, K ;
Nagasaka, K ;
Miyasaka, N .
AUTOIMMUNITY, 2005, 38 (05) :383-392